Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Cerilliant
Harvard Business School
US Department of Justice
UBS
Deloitte
US Army
McKinsey

Generated: June 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021433

« Back to Dashboard

NDA 021433 describes FLOVENT HFA, which is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from five suppliers. There are sixteen patents protecting this drug. Additional details are available on the FLOVENT HFA profile page.

The generic ingredient in FLOVENT HFA is fluticasone propionate. There are twenty-six drug master file entries for this compound. Eighty-three suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for 021433
Tradename:FLOVENT HFA
Applicant:Glaxo Grp Ltd
Ingredient:fluticasone propionate
Patents:16
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Respiratory Tract Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021433
Suppliers and Packaging for NDA: 021433
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433 NDA GlaxoSmithKline LLC 0173-0718 N 0173-0718-20
FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433 NDA GlaxoSmithKline LLC 0173-0718 N 0173-0718-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.22MG/INH
Approval Date:May 14, 2004TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 16, 2018Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Jun 23, 2018Product Flag?Substance Flag?Delist Request?

Expired US Patents for NDA 021433

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-003 May 14, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-002 May 14, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-002 May 14, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp Ltd FLOVENT HFA fluticasone propionate AEROSOL, METERED;INHALATION 021433-003 May 14, 2004 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
AstraZeneca
McKesson
Fish and Richardson
Accenture
Johnson and Johnson
Healthtrust
Moodys
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.